EUVIMEDEUVIMED entdecken
Crossref

Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer

Ellen Schenk, Magnus Essand, Robert Kraaij, Rachel Adamson, Norman Maitland, Chris H Bangma

Human Gene Therapy Clinical Development · 2014

DOI: 10.1089/hum.2013.181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy Clinical Development, 2014. Verfasst von Ellen Schenk und 5 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Schenk, E., Essand, M., Kraaij, R., Adamson, R., Maitland, N., & Bangma, C. H. (2014). Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer. Human Gene Therapy Clinical Development. https://doi.org/10.1089/hum.2013.181

Vancouver

Schenk E, Essand M, Kraaij R, Adamson R, Maitland N, Bangma CH. Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer. Human Gene Therapy Clinical Development. 2014. doi:10.1089/hum.2013.181

BibTeX
@article{Schenk2014,
  author = {Schenk, Ellen and Essand, Magnus and Kraaij, Robert and Adamson, Rachel and Maitland, Norman and Bangma, Chris H},
  title = {Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer},
  journal = {Human Gene Therapy Clinical Development},
  year = {2014},
  doi = {10.1089/hum.2013.181}
}
Kostenlos starten →